

# Marlies Wakkee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1714771/publications.pdf>

Version: 2024-02-01

52  
papers

1,427  
citations

471061

17  
h-index

344852

36  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1849  
citing authors

#	ARTICLE	IF	CITATIONS
1	Complex skin cancer treatment requiring reconstructive plastic surgery: an interview study on the experiences and needs of patients. Archives of Dermatological Research, 2022, 314, 25-36.	1.1	4
2	Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study. Journal of the American Academy of Dermatology, 2022, 86, 331-338.	0.6	32
3	A nationwide study of the incidence and trends of first and multiple basal cell carcinomas in the Netherlands and prediction of future incidence*. British Journal of Dermatology, 2022, 186, 476-484.	1.4	10
4	Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data*. British Journal of Dermatology, 2022, 186, 835-842.	1.4	14
5	Outcome after treatment for sebaceous carcinoma: A multicenter study. Journal of Surgical Oncology, 2022, 125, 730-735.	0.8	8
6	The impact of the COVID-19 pandemic on keratinocyte carcinoma in the Netherlands: Trends in diagnoses and magnitude of diagnostic delays. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 680-687.	1.3	16
7	Efficacy, cost-minimization, and budget impact of a personalized discharge letter for basal cell carcinoma patients to reduce low-value follow-up care. PLoS ONE, 2022, 17, e0260978.	1.1	4
8	Validation of a Market-Approved Artificial Intelligence Mobile Health App for Skin Cancer Screening: A Prospective Multicenter Diagnostic Accuracy Study. Dermatology, 2022, 238, 649-656.	0.9	18
9	Limited impact of COVID-19-related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumour characteristics: a nationwide pathology registry analysis. British Journal of Dermatology, 2022, 187, 196-202.	1.4	17
10	Process evaluation of a multicentre randomised clinical trial of substituting surgical excisions of low-risk basal cell carcinomas from secondary to primary care. BMJ Open, 2022, 12, e047745.	0.8	0
11	Assessment of the Diagnostic Accuracy of Baseline Clinical Examination and Ultrasonographic Imaging for the Detection of Lymph Node Metastasis in Patients With High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Dermatology, 2022, 158, 151.	2.0	7
12	Risk factors for metastatic cutaneous squamous cell carcinoma: Refinement and replication based on 2 nationwide nested case-control studies. Journal of the American Academy of Dermatology, 2022, 87, 64-71.	0.6	10
13	Polygenic risk scores for melanoma: a stepwise process towards clinical implementation. British Journal of Dermatology, 2022, 186, 768-768.	1.4	1
14	Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. British Journal of Dermatology, 2022, 187, 381-391.	1.4	14
15	What are the most important factors in basal cell carcinoma follow-up care? The perspective of patients. Skin Health and Disease, 2021, 1, e10.	0.7	0
16	Practice Variation in Skin Cancer Treatment and Follow-Up Care: A Dutch Claims Database Analysis. Dermatology, 2021, 237, 1000-1006.	0.9	6
17	What do patients and dermatologists prefer regarding low-risk basal cell carcinoma follow-up care? A discrete choice experiment. PLoS ONE, 2021, 16, e0249298.	1.1	1
18	Mobile health skin cancer risk assessment campaign using artificial intelligence on a population-wide scale: a retrospective cohort analysis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e772-e774.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Views on mobile health apps for skin cancer screening in the general population: an in-depth qualitative exploration of perceived barriers and facilitators*. <i>British Journal of Dermatology</i> , 2021, 185, 961-969.	1.4	16
20	Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study. <i>European Journal of Cancer</i> , 2021, 154, 111-119.	1.3	16
21	Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study. <i>Cancers</i> , 2021, 13, 4431.	1.7	12
22	Melanoma in older patients: declining gap in survival between younger and older patients with melanoma. <i>Acta Oncologica</i> , 2020, 59, 4-12.	0.8	9
23	Accuracy of a smartphone application for triage of skin lesions based on machine learning algorithms. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 648-655.	1.3	56
24	Predicting keratinocyte carcinoma in patients with actinic keratosis: development and internal validation of a multivariable risk prediction model. <i>British Journal of Dermatology</i> , 2020, 183, 495-502.	1.4	16
25	Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma. <i>JAMA Dermatology</i> , 2020, 156, 1300.	2.0	44
26	Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017. <i>JAMA Dermatology</i> , 2020, 156, 973.	2.0	22
27	Needs and preferences of patients regarding basal cell carcinoma and cutaneous squamous cell carcinoma care: a qualitative focus group study. <i>British Journal of Dermatology</i> , 2019, 180, 122-129.	1.4	35
28	Opportunities for improving the efficiency of keratinocyte carcinoma care in primary and specialist care: Results from population-based Dutch cohort studies. <i>European Journal of Cancer</i> , 2019, 117, 32-40.	1.3	9
29	Vismodegib for giant, locally advanced, basal cell carcinoma and its complex position in clinical practice. <i>JAAD Case Reports</i> , 2019, 5, 267-270.	0.4	6
30	Substitution of low-risk skin cancer hospital care towards primary care: A qualitative study on views of general practitioners and dermatologists. <i>PLoS ONE</i> , 2019, 14, e0213595.	1.1	12
31	Insight into the management of actinic keratosis: a qualitative interview study among general practitioners and dermatologists. <i>British Journal of Dermatology</i> , 2019, 181, 96-104.	1.4	18
32	Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2019, 181, 338-343.	1.4	67
33	Factors influencing current low-value follow-up care after basal cell carcinoma and suggested strategies for de-adoption: a qualitative study. <i>British Journal of Dermatology</i> , 2019, 180, 1420-1429.	1.4	8
34	Recurrence of periocular basal cell carcinoma and squamous cell carcinoma after Mohs micrographic surgery: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2019, 180, 1176-1182.	1.4	33
35	Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis. <i>British Journal of Dermatology</i> , 2019, 181, 544-553.	1.4	17
36	Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. <i>British Journal of Dermatology</i> , 2019, 180, 31-42.	1.4	21

#	ARTICLE	IF	CITATIONS
37	Development of Smartphone Apps for Skin Cancer Risk Assessment: Progress and Promise. <i>JMIR Dermatology</i> , 2019, 2, e13376.	0.4	35
38	Increased overall drug utilization in patients with psoriasis: a case-control study based on Dutch general practitioner data. <i>British Journal of Dermatology</i> , 2017, 176, 634-642.	1.4	6
39	Epidemiology of basal cell carcinoma: scholarly review. <i>British Journal of Dermatology</i> , 2017, 177, 359-372.	1.4	172
40	The four Ws of skin cancer surveillance in patients with melanoma: Why? Who? When? Where?. <i>British Journal of Dermatology</i> , 2017, 176, 839-841.	1.4	1
41	Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). <i>British Journal of Dermatology</i> , 2017, 176, 1599-1606.	1.4	18
42	Smokers versus Smoking: Is There Detection Bias for Keratinocyte Carcinomas?. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1614-1616.	0.3	0
43	Rising interest in the field of paediatric psoriasis. <i>British Journal of Dermatology</i> , 2016, 174, 1180-1181.	1.4	1
44	Kidney disease in moderate-to-severe psoriasis: commentary. <i>British Journal of Dermatology</i> , 2016, 174, 271-272.	1.4	0
45	Actinic keratosis in China: big numbers and small percentages. <i>British Journal of Dermatology</i> , 2016, 174, 954-954.	1.4	0
46	Epidemiology of Lentigo Maligna and Lentigo Maligna Melanoma in the Netherlands, 1989-2013. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1955-1960.	0.3	47
47	Dermatoepidemiology; what's up people?. <i>British Journal of Dermatology</i> , 2015, 173, 881-883.	1.4	1
48	Multivariable Analysis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1-5.	0.3	18
49	The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1542-1551.	0.3	301
50	Psoriasis Is Not Associated with Atherosclerosis and Incident Cardiovascular Events: The Rotterdam Study. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2347-2354.	0.3	102
51	Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohort. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1135-1144.	0.6	100
52	Comorbidities in Dermatology. <i>Dermatologic Clinics</i> , 2009, 27, 137-147.	1.0	35